| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.024 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |